Alex Goldberg

NASDAQ Active Stock Watch List: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) and PDL BioPharma, Inc. (NASDAQ:PDLI) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/15/2014 -- Equity Profile Report expands its NASDAQ Active Stock Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) and PDL BioPharma, Inc. (NASDAQ:PDLI).

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients closed down in its previous session (-0.12%) on 28,269,052 shares traded after ARIAD Announced to Host Conference Call and Webcast Discussion of Fourth Quarter and Year-End 2013 Financial Results on February 25, 2014. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently down (-62.61%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

PDL BioPharma, Inc. (NASDAQ:PDLI) a company that engages in intellectual property asset management and patent portfolio and related assets investment activities closed up in its previous session (+0.60%) on 2,878,438 shares traded after PDL BioPharma Retained Dr. Stephen Hoffman as Senior Advisor. PDL BioPharma, Inc. (NASDAQ:PDLI) is currently up (+24.63%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about PDL BioPharma, Inc. (NASDAQ:PDLI)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com